tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Harmony Biosciences price target lowered to $35 from $50 at Mizuho

Mizuho lowered the firm’s price target on Harmony Biosciences (HRMY) to $35 from $50 and keeps an Outperform rating on the shares. The firm cites the company’s negative Phase data for ZYN002 in fragile X syndrome for the target cut. However, Mizuho still sees a favorable risk/reward for the shares given the optionality with Harmony’s remaining pipeline.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1